SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (2233)1/3/2018 9:39:06 PM
From: Felix B  Read Replies (1) | Respond to of 3559
 
I agree I thought a biosimilar trap would be difficult to produce but I am no expert.

Also with the two eylea combos failing, other than the sBLA for dosing what is their next move? Sustained release? Lucentis has been trying that for ages with no luck...



To: Miljenko Zuanic who wrote (2233)1/8/2018 7:27:05 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3559
 
CHRS is another company developing an Eylea biosimilar, although its program is less advanced than MYL/MNTA's.